Eli Lilly and Company (NYSE:LLY) Issues Earnings Results, Beats Estimates By $2.22 EPS

Eli Lilly and Company (NYSE:LLY) issued its earnings results on Wednesday. The company reported $8.38 earnings per share for the quarter, beating analysts’ consensus estimates of $6.16 by $2.22, FiscalAI reports. The firm had revenue of $22.97 billion for the quarter, compared to analysts’ expectations of $20.69 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The firm’s revenue for the quarter was up 47.7% compared to the same quarter last year. During the same quarter last year, the firm earned $6.31 earnings per share. Eli Lilly and Company updated its FY 2026 guidance to 35.500-36.500 EPS.

Here are the key takeaways from Eli Lilly and Company’s conference call:

• Q2 revenue rose 48% year over year to $6.8 billion of incremental growth from key products, led by Mounjaro and Zepbound; non-GAAP EPS increased to $8.38 from $6.31.
• Lilly raised its 2026 outlook, increasing the revenue range to $85 billion-$87 billion and non-GAAP EPS guidance to $35.50-$36.50, reflecting stronger-than-expected first-half performance.
• Foundayo’s launch is gaining traction as access expands through major PBMs and the Medicare GLP-1 Bridge program; Lilly reported recent prescription acceleration, 36,000 U.S. prescribers, and encouraging initial international demand.
• The pipeline produced several important advances, including positive phase III retatrutide results, an FDA submission for orforglipron in diabetes, strong oncology data for pirtobrutinib and selpercatinib, and regulatory progress for weekly insulin efsitora alfa.
• U.S. net pricing declined, with reported price down 3% and an underlying decline of approximately 9% excluding rebate and discount adjustments; management also cautioned that prior-period adjustments and seasonal factors will affect second-half comparisons.

Eli Lilly and Company Price Performance

Eli Lilly and Company stock traded up $20.61 during mid-day trading on Thursday, hitting $1,190.47. The company’s stock had a trading volume of 1,854,786 shares, compared to its average volume of 3,135,317. The stock has a market capitalization of $1.12 trillion, a P/E ratio of 42.25, a P/E/G ratio of 1.39 and a beta of 0.51. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,249.45. The stock’s fifty day moving average price is $1,156.45 and its two-hundred day moving average price is $1,045.49. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date is Friday, August 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 24.58%.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on LLY shares. Weiss Ratings raised Eli Lilly and Company from a “buy (b-)” rating to a “buy (b)” rating in a research note on Wednesday, July 1st. Jefferies Financial Group raised their price target on shares of Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the company a “buy” rating in a report on Tuesday, June 9th. Barclays upped their price target on Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the stock an “overweight” rating in a report on Monday, May 4th. The Goldman Sachs Group reissued a “buy” rating and set a $1,283.00 price target on shares of Eli Lilly and Company in a report on Friday, May 22nd. Finally, Rothschild & Co Redburn upped their price target on shares of Eli Lilly and Company from $880.00 to $900.00 in a research report on Thursday, May 7th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $1,293.71.

Institutional Investors Weigh In On Eli Lilly and Company

Institutional investors and hedge funds have recently modified their holdings of the stock. Brighton Jones LLC grew its position in Eli Lilly and Company by 22.0% during the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock worth $7,409,000 after purchasing an additional 1,730 shares in the last quarter. Revolve Wealth Partners LLC boosted its position in shares of Eli Lilly and Company by 2.8% in the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock worth $1,136,000 after buying an additional 40 shares during the period. Schnieders Capital Management LLC. grew its holdings in shares of Eli Lilly and Company by 16.7% during the second quarter. Schnieders Capital Management LLC. now owns 7,993 shares of the company’s stock valued at $6,231,000 after buying an additional 1,141 shares in the last quarter. Flow Traders U.S. LLC purchased a new position in shares of Eli Lilly and Company during the second quarter valued at $356,000. Finally, Nebula Research & Development LLC acquired a new position in Eli Lilly and Company during the second quarter valued at $749,000. 82.53% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Quarterly results substantially exceeded expectations. Lilly reported $22.97 billion in second-quarter revenue, up approximately 48% year over year, while non-GAAP EPS of $8.38 exceeded the $6.16 consensus estimate. Eli Lilly easily tops quarterly estimates, raises outlook
• Positive Sentiment: GLP-1 demand remains the primary growth catalyst. Mounjaro sales rose 91%, and Mounjaro and Zepbound together generated nearly two-thirds of quarterly sales. Strong prescription demand and international expansion helped drive the beat. Eli Lilly Stock Jumps as Mounjaro Sales Surge
• Positive Sentiment: Lilly raised its full-year outlook again. The company now expects 2026 revenue of $85 billion to $87 billion, compared with prior guidance of $82 billion to $85 billion, and issued EPS guidance of $35.50 to $36.50. Investors view the increase as evidence that demand is outpacing earlier assumptions. Eli Lilly raises annual revenue forecast
• Positive Sentiment: Pipeline and access developments add longer-term support. Lilly said Foundayo adoption is accelerating, Medicare coverage is expanding for obesity treatment, and retatrutide is progressing toward a potential 2027 filing. Lilly is also widening early access to retatrutide for certain patients. LLY Q2 Earnings Call Raises Outlook
• Positive Sentiment: Analyst confidence remains high. Cantor Fitzgerald raised its price target from $1,350 to $1,410 and maintained an “overweight” rating, reinforcing expectations for additional upside after the earnings-driven advance. Cantor Fitzgerald raises Eli Lilly price target
• Neutral Sentiment: Competitive sentiment is favoring Lilly. Novo Nordisk also beat estimates and raised guidance, but its weaker market reaction highlights Wall Street’s growing preference for Lilly’s execution and GLP-1 growth profile. LLY remains valued at a premium, making future results and supply execution important.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.